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Introduction
Perinatal hypoxia-ischemia affects approximately 2 to 4 per 1,000 term infants and a much greater proportion of preterm infants. Despite improved methods of intrapartum monitoring and advances in neonatal care and treatment, neonatal hypoxic-ischemic injury produces significant morbidity and mortality, often leading to long-term neurologic consequences. Neurologic sequelae of hypoxic-ischemic encephalopathy include delayed motor development, mental retardation, learning disabilities, seizure disorders, and cerebral palsy. The mechanisms underlying this injury are complex and are the focus of both current and future investigation. This article examines some of the major biochemical pathways fundamental to the development of hypoxic-ischemic brain injury and describes approaches that are being investigated to reduce or prevent neuronal injury and death.
Energy Failure
Under normal physiologic conditions, the energy balance of the brain is maintained through oxidative phosphorylation and the production of adenosine 5Ј-triphosphate (ATP). Hypoxia-ischemia produces an imbalance in metabolic demand and cellular energy supply that results in the disruption of critical cellular processes. Oxidative phosphorylation initially fails during a state of insufficient tissue oxygen levels because oxygen is the ultimate electron acceptor in the electron transport chain of the citric acid cycle. During hypoxia, cells attempt to meet energy demands through increased cerebral blood flow and anaerobic metabolism. A reservoir of high-potential phosphoryl groups exists in the form of phosphocreatine (PCr). PCr levels can be depleted in efforts to maintain optimal ATP levels. When these efforts fail to meet energy requirements, the uncompensated cells become injured. (Fig. 1 .) Hypoxia-ischemia causes an elevation of the excitotoxic amino acid glutamic acid (glutamate) as a result of enhanced presynaptic release and dysfunctional energy-dependent uptake mechanisms. The decline in the cell membrane Na ϩ , K ϩ -ATPase activity and the inability of the cell to maintain ionic gradients leads to increased osmotic forces within the cell. Primary neuronal cell death can occur at this stage due to cell swelling and lysis. Excessive stimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate can lead to further neuronal injury and degeneration. Increased extracellular glutamate concentrations can activate the NMDA receptor, leading to increased cytosolic (intracellu-lar) calcium and the generation of oxygen free radicals. When calcium influx is unregulated, activation of phospholipases, proteases, and endonucleases can cause cell membrane, organelle, and nuclear disruption; the result is secondary neuronal cell injury and death. Following an acute hypoxic-ischemic insult, reperfusion and reoxygenation can activate multiple biochemical pathways. Delayed cell death can follow a secondary energy failure caused by the further release of excitotoxic amino acids, intracellular calcium accumulation, activation of nitric oxide synthesis, ongoing free radical production, and the release of cytokines, which lead to the triggering of apoptosis (programmed cell death). The extent of secondary or delayed injury may predict long-term neurodevelopmental outcome.
Neuroprotective strategies focus on altering the biochemical consequences of the post-hypoxicischemic reoxygenation injury. Interventions employed to decrease cerebral metabolic rate to diminish the depletion of high-energy phosphates and to reduce the cascade of biochemical events during reperfusion and reoxygenation include treatment with high-dose barbiturates or hypothermia. The use of hypothermia following hypoxiaischemia is being investigated and may show promise as a useful neuroprotective strategy in the newborn (see accompanying article by Gunn and Bennet).
NMDA Receptor, Excitatory Amino Acids, and Intracellular Calcium
Under normoxic conditions, neuronal intracellular calcium is maintained at low physiologic levels via oxygen and ATP-dependent mechanisms. During hypoxiaischemia, ATP levels fall, leading to prolonged cell membrane depolarization and disruption of cellular sodium and calcium ion homeostasis (Fig. 2) . The resulting excessive calcium influx through voltagesensitive calcium channels can initiate the release of excitatory amino acids, specifically glutamate. The increase in postsynaptic glutamate concentrations can activate the NMDA receptor, leading to a further increase in cytosolic calcium. Other nonNMDA glutamate receptors, such as alphaamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors, may contribute to disturbances in neuronal cell ion homeostasis and calcium regulation.
Calcium accumulation in the cytosol (within the cell) also can occur via other mechanisms. Following an initial influx of extracellular calcium, the release of intracellular stores within the endoplasmic reticulum and the mitochondria cause a further increase in cytosolic calcium and (Table 1) , including the generation of free radicals. The increased free radical generation increases peroxidation of cellular and subcellular membranes. In addition, increased intracellular calcium may lead to increased intranuclear calcium. The nuclear envelope usually acts as a nucleocytoplasmic barrier to calcium, insulating it from large changes in cytosolic calcium. A high-affinity Ca ϩϩ -ATPase and an inositol 1,3,4,5, tetrakisphosphate (IP4) receptor, both located on the outer nuclear membrane, as well as an inositol 1,4,5, triphosphate (IP3) receptor on the inner nuclear membrane regulate intranuclear calcium.
Nuclear calcium signals control a number of critical nuclear functions, including transcription regulation, cell cycle regulation, gene transcription, DNA replication, and nuclear envelope breakdown. Under conditions of hypoxia-ischemia, increased intracellular calcium and disruption of the nuclear calcium regulation may lead to increased intranuclear calcium. Increased intranuclear calcium can initiate the expression of proapoptotic genes and the activation of endonucleases, leading to fragmentation of nuclear DNA and programmed cell death.
The inhibition or blocking of voltage-sensitive calcium channels and NMDA receptors to regulate or block calcium entry into the cell following hypoxia-ischemia has been investigated as a neuroprotective strategy in the newborn. Various calcium channel blockers have been investigated and shown some beneficial effects under experimental conditions, but they demonstrate adverse cardiovascular effects under clinical conditions. In experimental studies, MK-801, a specific blocker of the NMDA receptor, has been associated with an improved neuronal outcome following hypoxic-ischemic conditions. However, this agent possesses many undesirable adverse affects, including potential neurotoxicity, making its use clinically unacceptable.
Magnesium sulfate has been used extensively for the treatment of preeclampsia or as a tocolytic agent in obstetrics. The use of magnesium as a calcium channel blocker has been studied following reports suggesting that infants born to mothers treated with magnesium sulfate were less likely to develop cerebral palsy. This implies that magnesium sulfate may provide neuroprotection to susceptible newborns. Magnesium acts as a noncompetitive antagonist of the NMDA receptor-blocking voltage-dependent calcium entry into the neuronal cell. Under normal physiologic conditions, it assists in maintaining ionic homeostasis by inhibiting NMDA receptor activation and preventing receptor activation. Under hypoxic conditions, depolarization of the neuron modifies both the membrane potential and ionic homeostasis, thereby disrupting the voltage-dependent magnesium blockade. Increasing the extracellular and intracellular levels of magnesium may help to restore voltage-dependent magnesium blockade or block the NMDA calcium channel itself, reducing calcium entry into the cell and the ensuing excessive release of glutamate. Evaluation of magnesium sulfate as a neuroprotective agent in the 
Free Radical Generation
Free radicals, unstable reactive atoms of molecules containing an odd number of electrons in their outer orbit, and reactive oxygen species (ie, superoxide, hydrogen peroxide, and hydroxyl radical) can injure the brain during hypoxia-ischemia and particularly during reperfusion and reoxygenation. Multiple biochemical reactions can generate oxygen free radicals (Table 2) . Under conditions of decreased oxygen, mitochondrial cytochrome oxidase is not adequately saturated, and levels of reduced forms of the electron transport chain components, specifically superoxide anion, increase. Free radicals subsequently leak from the mitochondria into the cytoplasm. Excessive activation of NMDA and nonNMDA receptors during oxidative stress leads to increased accumulation of intracellular calcium. Free radicals can be generated when increased intracellular calcium activates: 1) phospholipase A 2 , triggering prostaglandin synthesis from arachidonic acid through the cyclooxygenase and lipoxygenase pathways; 2) nitric oxide synthase and peroxynitrite formation; and 3) proteases, which can lead to the conversion of xanthine dehydrogenase to xanthine oxide. Xanthine oxidase can generate oxygen free radicals as it catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid in the terminal steps of purine nucleotide degradation. An additional mechanism of free radical generation during hypoxia-ischemia is the release of transition metal ions from their binding proteins. Specifically, free Fe ϩϩ can catalyze the formation of hydroxyl radicals and other iron-oxygen compounds. Furthermore, free radicals may trigger the release of additional excitatory amino acid neurotransmitters and increase the affinity of the NMDA receptor. These effects may drive additional NMDA receptor-mediated excitotoxicity.
During hypoxia-ischemia, the generation of oxygen free radicals can lead to cellular injury through damaging effects on membrane phospholipids. Unsaturated fatty acyl groups of phospholipids and cholesterol are targets of oxidative attack by free radicals, which can initiate lipid peroxidation. Cytotoxic effects of lipid peroxidation include altered structure and fluidity of lipid bilayers, lyso- Free radical chain reactions are autocatalytic and will continue until terminated by antioxidants. Endogenous free radical scavengers include cholesterol, alphatocopherol (vitamin E), ascorbic acid (vitamin C), and thiol-containing compounds (eg, glutathione). Among the intrinsic defense mechanisms against free radical formation are such enzymes as superoxide dismutase, catalase, and peroxidase. Concentrations of oxygen radical scavengers are low in preterm infants; they do not reach peak values until near term. Experimental approaches to reduce cellular injury under hypoxic-ischemic conditions can be directed toward improving the termination of free radical chain reactions by increasing antioxidants or by preventing the formation of free radicals.
Vitamin C is a major antioxidant in the developing fetal brain, with high levels present late in the third trimester. However, vitamin C levels decline rapidly following birth in association with increased oxidant production. Experimental studies suggest that vitamin C may have a neuroprotective effect following a hypoxiaischemia insult. Unfortunately, the optimal dose of vitamin C for neuroprotection is not known, and excessive doses may be associated with inhibition of protein synthesis and late neuronal death.
Vitamin E is a lipid-soluble antioxidant that acts as a prime antioxidant in cell membrane lipid bilayers. Administration of vitamin E in experimental studies has been associated with a reduction in neuronal injury during hypoxia-ischemia as well as subsequent reperfusion and reoxygenation. Because the vitamin is lipid-soluble, it must be administered for days prior to an insult to reach effective concentrations in the brain, which makes its use clinically impractical.
Iron chelators, such as deferoxamine, have been evaluated for their ability to reduce free Fe ϩϩ and irondependent reactions that catalyze the formation of toxic hydroxyl free radicals and the stimulation of lipid peroxidation during hypoxia-ischemia. Studies have demonstrated that deferoxamine can decrease free radical production and diminish oxidative brain damage, but it also exhibits potential negative cardiovascular effects.
Inflammatory Mediators
The triggering of inflammatory mechanisms following hypoxia-ischemia plays an important biochemical role in the cascade of events leading to associated neuronal cell death. Microglial cells are activated in the early period after the initial insult, resulting in the release of excitatory amino acids, reactive oxygen species, nitric oxide, proteases, and cytokines. The cytokines, interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNFalpha), increase markedly in the brain following hypoxicischemia, and both are principal mediators of the posthypoxic-ischemic inflammatory and immune response. IL-1-beta and TNF-alpha can activate endothelialleukocyte adhesion molecules. Adherent leukocytes can lead to microvascular damage and vascular infiltration following the release of cytotoxic factors such as reactive oxygen species and cytokines. TNF-alpha also may have direct toxic effects. IL-1-beta may lead to apoptotic cell death when acted on by specific proteases. Reperfusion and reoxygenation promote the metabolism of arachidonic acid by phospholipase A 2 and can generate platelet-activating factor (PAF). PAF can enhance endothelial-leukocyte adhesion by stimulating neutrophils to release oxygen free radicals, thereby aggravating the inflammatory response. Altering the inflammatory response to hypoxiaischemia by reducing cytokine release or by treatment with antagonists, such as IL-1-beta, TNF-alpha, or PAF antagonists, may help to ameliorate neuronal injury. Experimental studies of anti-inflammatory therapies may provide important advances in modulating post-hypoxicischemic brain injury.
Nitric Oxide Synthase
Nitric oxide synthase (NOS) is present in cerebral endothelial cells, astrocytes, and neuronal cells. NOS produces nitric oxide (NO⅐), a highly diffusible gas and free radical that, under normal conditions, functions as an important cell-signaling mediator to regulate various intracellular activities, including neurotransmission. Three isoforms of NOS have been recognized. Neuronal NOS (nNOS) acts as a neuromodulator, promotes synaptogenesis and remodeling, and is involved in longterm potentiation. Endothelial NOS (eNOS) is fundamental in the regulation of vascular tone, specifically vasodilation. Both nNOS and eNOS are activated by calcium. An inducible form of nitric oxide synthase (iNOS), which is calcium-independent, is present in macrophages, astrocytes, and microglia and is inducible by cytokines. During hypoxia-ischemia and subsequent reoxygenation-reperfusion, NOS increases significantly neurology hypoxic-ischemic encephalopathy and may have both beneficial vascular and neurotoxic effects. Endothelial NOS may exert a neuroprotective function by enhancing vasodilation and perfusion in the brain during hypoxia-ischemia. However, excessive production of nNOS, which can be generated by NMDA receptor activation, can have significant neurotoxicity. NO⅐ produced by nNOS may damage neuronal DNA directly. In addition, the reaction of NO⅐ with superoxide leads to generation of the highly toxic peroxynitrite and hydroxyl free radicals. Inducible NOS may contribute to ongoing or delayed neurotoxicity as it is stimulated by the inflammatory effects (ie, cytokines) that are present following reoxygenation and reperfusion.
NOS inhibitors have been considered as a possible approach for lessening hypoxic-ischemic brain injury. Studies have demonstrated that nonselective NOS inhibitors may reduce free radical-mediated neuronal injury, but there is concern that inhibition of eNOS may blunt the beneficial effects of post-hypoxic-ischemic vasodilation. Selective inhibition of nNOS or iNOS, however, may offer to a promising approach for attenuating hypoxic-ischemic brain injury in the newborn.
Xanthine Oxidase
During an energy deficit, ATP is broken down to adenosine 5Ј-diphosphate (ADP), adenosine monophosphate (AMP), adenosine, inosine, and hypoxanthine. Under aerobic conditions, hypoxanthine is converted to xanthine and then to uric acid by xanthine dehydrogenase, using nicotinamide adenine dinucleotide (NAD) as a substrate. However, in hypoxic-ischemic conditions, a Ca ϩϩ -activated protease mediates the conversion of xanthine dehydrogenase to xanthine oxidase. Xanthine oxidase generates the free radical superoxide as it metabolizes hypoxanthine to xanthine and xanthine to uric acid in the terminal steps of purine nucleotide degradation (Fig. 3) . Superoxide radicals can react further with hydrogen peroxide to produce highly reactive hydroxyl radicals. The conversion of hypoxanthine to xanthine is the first irreversible step in the catabolic breakdown of ATP. Accordingly, accumulation of hypoxanthine during hypoxia potentially supplies substrate for the production of free radicals by xanthine oxidase during reoxygenation and reperfusion. The level of xanthine oxidase in the brain is believed to be relatively low compared with other tissues, although its activity may be enriched in the microvascular endothelium.
Allopurinol, a specific inhibitor of xanthine oxidase, can inhibit the breakdown of hypoxanthine to uric acid during hypoxia-ischemia and following reoxygenation and reperfusion. Both allopurinol and its active metabolite, oxypurinol, also can act as free radical scavengers. Allopurinol can inhibit xanthine oxidase at low doses, but inhibition of free radical production during hypoxia appears to be dose-dependent, an effect that likely is related to its action as a free radical scavenger. Allopurinol may act via other mechanisms to reduce cellular injury during cerebral hypoxia-ischemia. For example, it may have metal chelating properties that will inhibit free Fe ϩϩ and iron-dependent catalyzed reactions. By preventing the metabolism of hypoxanthine to xanthine and uric acid, allopurinol may preserve levels of high-energy metabolites during hypoxia by inhibiting purine degradation. It also may improve restoration of the cellular energy state by reuse of inosine and hypoxanthine through salvage pathways at a lower energy cost to the cell. Allopurinol inhibition of xanthine oxidase could lead to the accumulation of purines, including adenosine. Increased levels of adenosine may attenuate the activity of the NMDA receptor by inhibiting the release of the excitotoxic amino acid glutamate. In addition, adenosine may induce a hyperpolarizing outward potassium current that could help to maintain a voltage-dependent block of NMDA receptors, thus reducing NMDA receptor-mediated calcium influx and excitotoxicity. Other adenosine-potentiating treatments, such as adenosine agonists or adenosine uptake inhibitors, may demonstrate neuroprotective properties.
Experimental studies have shown that allopurinol may preserve the cellular energy state, inhibit lipid peroxidation, attenuate modifications of the NMDA receptor, inhibit neutrophil lysosomal enzyme release, and reduce the expression of apoptotic proteins during hypoxia-ischemia. Treatment with allopurinol following reoxygenation and reperfusion also appears to offer some benefit. Clinical studies have been limited, but allopurinol appears to be safe when administered to newborns and effectively inhibits xanthine oxidase during reoxygenation and reperfusion. Allopurinol may reduce central nervous system morbidity following hypoxia-ischemia, but further investigation is needed.
Apoptosis, Caspases, and Gene Regulation
Apoptosis (programmed cell death) may be responsible for a significant portion of neuronal cell death following hypoxia-ischemia, particularly that which occurs days to weeks following an insult. During hypoxia-ischemia, increased intracellular calcium may lead to increased intranuclear calcium, which may promote increased endonuclease activity, alter gene expression, and direct apoptosis. Apoptosis is an active process that involves gene activation and expression, leading to specific endonucleolytic cleavage of nuclear DNA.
The apoptotic process is driven by intracellular caspases, a group of cysteinyl-aspartate proteases. Some caspases act as proinflammatory agents or initiators of apoptosis; others serve as cell executioners. Initiation of the caspase pathway requires dimerization of select caspase proenzymes. One mechanism of caspase activation involves dimerization of caspase-9-monomers, which can be induced to join through the binding of cytochrome c. Under normal conditions, caspase-9-monomers and cytochrome c are separated by the mitochondrial membrane. When the membrane is disrupted, cytochrome c is released from the mitochondria, allowing activation of caspases. The Bcl-2 family of proteins regulates the integrity of the mitochondrial membrane. The Bcl-2 family consists of both cell death promoters, such as Bax and Bad, and cell death preventers, such as Bcl-2 and Bcl-xl. These homologs of the Bcl-2 family can dimerize through protein-protein interactions to form homodimers or heterodimers. Bcl-2 and Bax proteins both are expressed in neurons of the central nervous system. When Bax protein is overexpressed, it can dimerize with itself and promote caspase activation, which accelerates the apoptotic pathway. When Bcl-2 protein is overexpressed, it can dimerize with Bax and repress cell death. The ratio of Bcl-2 to Bax protein may determine a cell's susceptibility to apoptosis following hypoxiaischemia. In addition, both Bax and Bcl-2 can undergo posttranslational modification, which may alter their function and regulate apoptosis. Early experimental studies suggest that caspase inhibitors may offer neuroprotection for neuronal cells at risk for apoptosis. Advances in the understanding and modification of genes, gene expression, and posttranslational modifications fol- 
Conclusion
The biochemical mechanisms involved in post-hypoxicischemic neuronal injury and death are exceedingly complex and interdependent and may vary according to clinical conditions. Although individual interventions or treatments may be successful in attenuating specific effects of hypoxia-ischemia (Table 3 ), a single strategy or treatment may not be clinically effective in reducing neonatal brain injury. A broader, wide range approach that targets multiple biochemical and physiologic disturbances at the appropriate time may be necessary to affect the neurologic sequelae of hypoxic-ischemic encephalopathy successfully. As our understanding of the complex biochemical pathways involved in the evolution of neuronal injury and death following hypoxia-ischemia expands, further advances in developing safe and clinically useful modalities and strategies to prevent or attenuate neonatal hypoxic-ischemic encephalopathy may be realized.
